2026-09-20T07:45:26Z rgu-repository.worktribe.com

oai:rgu-repository.worktribe.com:248877 2026-09-04T14:56:28Z 084104101115105115 openaccess

Thesis Characterisation of cysteamine prodrugs for the treatment of cystinosis and evaluation of liquid fill technology. Cystinosis is a rare, autosomal, recessive disease characterised by raised levels of the amino acid cystine in the cells of most organs in the body which can cause organ damage. The treatment involves the oral administration of the aminothiol, cysteamine (Cystagon(TM)), but this has an offensive taste and smell, can cause vomiting and its metabolites are excreted from the body via breath (halitosis) and sweat, which can cause poor patient compliance. The main research aim was to characterise two cysteamine prodrugs for the treatment of cystinosis and evaluate the suitability of liquid fill technology using prodrugs, or alternative drug models, to determine excipient usage using solubility, stability and capsule shell compatibility data to potentially develop prototype formulations based on liquid fill technology. McCormick, John James MRes Masters 2016-05-31 oai:rgu-repository.worktribe.com:248877 https://rgu-repository.worktribe.com/248877/1/MCCORMICK%202016%20Characterisation%20of%20cysteamine%20prodrugs RGU Internal Funding Cystinosis Formulation Capsules Encapsulation Modified release Gelucire Liquid fill technology http://hdl.handle.net/10059/2138 2016 en openAccess https://creativecommons.org/licenses/by-nc-nd/4.0/ Public